Key Players
Competitive Landscape
Continuous-glucose-monitor-guided nutrition draws four business models: biosensor owners, guided metabolic programs, wearable platforms and nutrition-software specialists. Abbott and Dexcom control sensor economics. Signos and Levels Health package interpretation with paid programs. Veri, January AI and Hello Inside compete mainly through food-response software and adjacent wearable data.
Investment shifted toward broader consumer-health platforms during 2026 as biosensor companies extended glucose data into meal decisions and related health signals. In June 2026, Dexcom announced a rebuilt Stelo app plus planned international expansion. In August 2026, Abbott partnered with Google to link Lingo glucose signals with Fitbit data and AI. The competitive test is how much useful guidance each platform provides after sensing starts.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| In June 2026, the FDA cleared Dexcom Stelo for people aged two years and older who do not use insulin. | Families and younger users need a nonprescription path to glucose feedback outside insulin treatment. | OTC biosensing is expanding beyond adult-only wellness access. | Age expansion can widen nutrition-guidance use cases if programs maintain pediatric claim and consent boundaries. |
| In February 2026, Levels introduced Levels Pro for practitioners using CGM, labs, food logs and lifestyle data in one shared view. | Practitioners need one place to review metabolic inputs during nutrition counseling. | Consumer metabolic platforms are extending into practitioner-supported workflows. | Provider-facing memberships can support higher-touch coaching without relying on sensor sales alone. |
| In June 2026, ŌURA and LillyDirect announced a collaboration for behavioral support tools used alongside prescribed GLP-1 treatment. | People using obesity medicines need behavioral support that extends beyond medication supply. | Wearable platforms are moving deeper into metabolic-health support beside prescribed treatment. | Veri nutrition expertise gives Oura a route to pair food guidance with broader metabolic monitoring. |
Signos, Nutrisense, January AI and Hello Inside compete outside the development table through dietitian support, predictive food-response analysis and localized meal interpretation.
Source: Future Market Insights, Continuous-Glucose-Monitor-Guided Nutrition and Continuous Glucose Monitoring Systems Market Reports, 2026-2036.
Leading companies cover biosensor access, meal-response software, human coaching and app-led program delivery through distinct commercial models.
Who leads the continuous-glucose-monitor-guided nutrition market?
Abbott and Dexcom hold the strongest biosensor positions, while Signos, Levels Health and Nutrisense compete more heavily on guided interpretation and coaching.
Which suppliers have documented qualification or quality approvals?
Dexcom has a June 2026 FDA clearance for broader OTC Stelo use, while Signos holds an FDA-cleared OTC glucose-monitoring pathway for adults not using insulin.
Which companies provide metabolic health and prediabetes products?
Levels Health, Nutrisense, Veri (ŌURA), January AI and Hello Inside provide metabolic or nutrition guidance built on glucose or meal-response data.
Which suppliers serve North America and Western Europe?
Abbott serves the United States and United Kingdom through Lingo, while Hello Inside serves selected European markets and Oura distributes its app more broadly.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| Abbott (Lingo) | Global biosensor owner with Lingo for consumer wellness and Libre platforms that also extend glucose data into meal guidance. | In January 2026, Abbott launched Libre Assist inside the Libre app to predict a meal’s glucose impact and provide personalized food guidance before sensor confirmation. |
| Signos | USA metabolic-health program built around an FDA-cleared OTC glucose system, app guidance and nutrition support. | In July 2026, Signos expanded its offer with Signos+, a 12- or 24-week program pairing Stelo biosensors with clinician-guided GLP-1 treatment and nutrition coaching. |
| Dexcom (Stelo) | OTC biosensor owner extending Stelo data into preventive programs and nutrition-linked digital health workflows. | In July 2026, Dexcom became the first company selected for the FDA TEMPO pilot, including a program that links G7 or Stelo data with nutrition and other health information. |
| Levels Health | USA metabolic-health program pairing CGM data with food logging, laboratory testing and clinician-supported guidance. | In July 2026, Levels began offering Dexcom Stelo to members, lowering prescription friction for people entering glucose-guided metabolic programs. |
| Nutrisense | USA metabolic-health program pairing Stelo glucose data with registered-dietitian coaching and app-based nutrition guidance. | In June 2026, Dexcom announced an agreement to acquire Nutrisense, subject to closing conditions and regulatory approvals, to extend personalized nutrition coaching beside glucose biosensing. |
| Veri (ŌURA) | Nutrition and metabolic-health specialist represented within Oura’s wearable platform after its acquisition by ŌURA. | In June 2025, Veri announced that it had joined ŌURA, moving its nutrition and metabolic-health expertise into a broader wearable platform. |
| January AI | Food-response software company using CGM data and predictive nutrition models without owning the biosensor. | In June 2025, January AI introduced blood-test uploads that feed laboratory results into personalized nutrition guidance inside the January app. |
| Hello Inside | European consumer metabolic-health program focused on CGM-linked food feedback and app-based nutrition experiments. | In December 2025, Hello Inside introduced an AI Meal Tracker that synchronizes photographed meals with continuous glucose data for meal-response analysis. |
Research Methodology
The companies mapped here illustrate the continuous-glucose-monitor-guided nutrition market structure rather than an exhaustive ranking. Inclusion requires current, verifiable evidence that a company supplies a CGM-linked nutrition program, food-response application, biosensor pathway or related guidance service within the defined market scope. Evidence comes from regulatory approvals, third-party certifications, company announcements, product documentation, and public filings. Capabilities are attributed to the stated CGM-linked program, application or service line rather than generalised across broader corporate portfolios. Market-share estimates remain proprietary FMI assessments for the forecast period.
